What Is the Typical Timeline for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Surveillance to Individual Legal Recourse

If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), understanding the timeline of adverse event reports is crucial. The legacy of pharmaceutical safety surveillance provides a framework for monitoring such rare but serious risks. This page outlines the reported onset patterns and what they mean for patients.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. The mechanism linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs normal immune surveillance. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune control is compromised. The prescribing information identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration—especially beyond two years—further increases that risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

Clinical presentation of PML can be subtle and variable. Symptoms may include progressive weakness, visual disturbances, cognitive decline, and coordination problems. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists frequently reported adverse events such as fatigue, gait disturbance, balance disorder, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms can overlap with those of multiple sclerosis, making diagnosis challenging. Diagnosis of PML typically requires MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The prescribing information emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations for affected patients. The boxed warning is prominent, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide and sign an enrollment form acknowledging the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients were adequately informed about the specific risk factors, such as the significance of anti-JCV antibody status or the increased risk with longer treatment duration.

Statute of Limitations for Tysabri Claims in New York

For patients who developed PML, the timeline between exposure and documented harm is critical. PML can occur after months to years of Tysabri treatment, and the prescribing information notes that herpes infections have been reported "from a few months to several years" after starting therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). A similar latency period applies to PML. For patients in New York considering legal action related to Tysabri-associated PML, the statute of limitations is a key factor. In New York, the statute of limitations for personal injury claims generally is three years from the date of injury. For medical malpractice claims, the statute is typically 2.5 years from the date of the alleged malpractice or from the end of continuous treatment. However, the discovery rule may apply, meaning the clock starts when the injury is discovered or reasonably should have been discovered. Given that PML symptoms can be insidious and may initially be attributed to the underlying disease, the date of discovery can be complex. Patients who developed PML after Tysabri treatment should consult with an attorney to determine the applicable deadline based on their specific circumstances. Attorney-related considerations include evaluating whether the manufacturer provided adequate warnings, whether the prescribing physician followed recommended monitoring protocols, and whether the patient was informed of risk factors such as anti-JCV antibody status.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury, and for medical malpractice claims, it is typically 2.5 years from the date of the alleged malpractice or end of continuous treatment. However, the discovery rule may apply, meaning the clock starts when the injury is discovered or reasonably should have been discovered. Given the insidious onset of PML, consulting an attorney is crucial to determine the applicable deadline.

What are the key risk factors for developing PML while on Tysabri?

According to the FDA-approved prescribing information, the three key risk factors are: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive and have been on Tysabri for longer periods are at higher risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.